Maria Caterina De Grandis
Overview
Explore the profile of Maria Caterina De Grandis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon
Pretta A, Ziranu P, Perissinotto E, Ghelardi F, Marmorino F, Giampieri R, et al.
Br J Cancer
. 2024 Nov;
132(2):188-194.
PMID: 39604610
Background: Despite a reduction of both incidence and mortality from CRC, recent studies have shown an increase in the incidence of early-onset CRC (EO-CRC). Data on this setting are limited....
2.
Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, et al.
Liver Int
. 2024 Mar;
44(5):1108-1125.
PMID: 38517286
Introduction: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours...
3.
Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis M, Germani M, et al.
Eur J Cancer
. 2023 Nov;
195:113396.
PMID: 37924647
Background: Upfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type mCRC. Molecular 'hyperselection' may optimize EGFR inhibition by detecting additional resistance alterations....
4.
De Grandis M, Ascenti V, Lanza C, Di Paolo G, Galassi B, Ierardi A, et al.
Int J Mol Sci
. 2023 Aug;
24(16).
PMID: 37628865
Despite the advances made in treatment, the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal, even in the locoregional and locally advanced stages, with high relapse rates after surgery. PDAC...
5.
Grizzi G, Salati M, Bonomi M, Ratti M, Holladay L, De Grandis M, et al.
Int J Mol Sci
. 2023 Jun;
24(11).
PMID: 37298371
Gastric cancer (GC) is still one of the most aggressive cancers with a few targetable alterations and a dismal prognosis. A liquid biopsy allows for identifying and analyzing the DNA...
6.
Piva V, De Grandis M, Zuin I, Angerilli V, Nappo F, Alfieri R, et al.
Updates Surg
. 2022 Oct;
75(2):305-312.
PMID: 36272058
Gastroesophageal adenocarcinoma is a challenging disease due to its poor prognosis and the presence of few therapeutic options. For these reasons, it is mandatory to identify the subgroup of patients...